is fedratinib a safe and efficacious treatment option for patients with pmf and low platelet counts?
Published 4 years ago • 50 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
2:13
dr. mesa on the efficacy of fedratinib in patients with myelofibrosis and low platelet counts
-
4:41
is pacritinib safe and efficacious for patients with mf who failed ruxolitinib?
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
2:03
preliminary results of a phase ii study of fedratinib in patients with mds/mpn and cnl
-
1:24
the promising role of pacritinib for the treatment of patients with mf and severe thrombocytopenia
-
1:27
real-world use of fedratinib in patients with mf who have failed on ruxolitinib
-
3:05
ruxolitinib, pacritinib, fedratinib or momelotinib for thrombocytopenic patients with myelofibrosis
-
1:15
pacritinib – is it safe for treating mf?
-
10:54
how should conditioning be performed before transplanting a patient with mf?
-
5:23
doctor explains low platelet count (thrombocytopenia) | causes, symptoms and more
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
1:52
maic of momelotinib versus fedratinib safety in myelofibrosis
-
4:12
pacritinib for patients with mf across the cytopenic spectrum
-
1:16
using rwd to evaluate the use of fedratinib as a potential bridge to hsct in patients with mf
-
0:46
the role of pacritinib in managing thrombocytopenia in patients with myelofibrosis
-
1:28
indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis